News
BMRA
0.5882
+5.04%
0.0282
Weekly Report: what happened at BMRA last week (0429-0503)?
Weekly Report · 1d ago
Biomerica jumps on signing multi-year distribution deal with major UAE healthcare company
Seeking Alpha · 04/29 12:53
Weekly Report: what happened at BMRA last week (0422-0426)?
Weekly Report · 04/29 12:28
BIOMERICA AND LEADING UAE HEALTHCARE COMPANY FORGE A PATH TO ENHANCED COLORECTAL AND BREAST SCREENING WITH EXCLUSIVE MULTI-YEAR DISTRIBUTION AGREEMENT
Reuters · 04/29 12:19
Weekly Report: what happened at BMRA last week (0415-0419)?
Weekly Report · 04/22 12:10
12 Health Care Stocks Moving In Monday's Pre-Market Session
Soligenix (NASDAQ:SNGX) stock increased by 95.1% to $0.75 during Monday's pre-market session. The company's market cap stands at $7.9 million. Cartesian Therapeutics and Longeveron also moved upwards. Losers Marinus Pharma and PaxMedica stock decreased by more than 20%.
Benzinga · 04/15 12:07
Weekly Report: what happened at BMRA last week (0408-0412)?
Weekly Report · 04/15 12:00
Biomerica Advances IBS Treatment with inFoods Product, Expands Physician Network Nationwide
Biomerica has expanded its reach with adoption by new offices in targeted regions, including the Southeast, Northeast and Midwest. The Company has activated over 30 new physician groups for the inFoods IBS product. The average increase in the number of physicians prescribing in foodys more than doubled each quarter.
Benzinga · 04/15 11:54
BIOMERICA INC: RECEIVES NOTICE OF ALLOWANCE FOR FIVE NEW PATENTS IN EUROPE, CANADA AND JAPAN
Reuters · 04/15 11:47
Biomerica provides update on inFoods® IBS expansion
Barchart · 04/15 06:47
Reported Late Friday, Biomerica Q3 EPS $(0.11) Up From $(0.12) YoY, Sales $1.02M Down From $1.11M YoY
Biomerica reported quarterly losses of $0.11 per share. The company reported $1.02 million in sales this quarter. Biomerica's sales for the quarter were down 8.46 percent from the same period last year. The stock is down 2.8 percent today.
Benzinga · 04/15 06:20
Biomerica GAAP EPS of -$0.11, revenue of $1M
Biomerica reports Q3 GAAP EPS of -$0.11, revenue of $1M (-9.1% Y/Y). The company maintained a cash and equivalents balance of $5.3 million as of February 29, 2024. Biomerica is expected to report fiscal year 2024 results on April 15.
Seeking Alpha · 04/15 04:53
BMRA Stock Earnings: Biomerica Reported Results for Q3 2024
Biomerica reported results for the third quarter of 2024. The company reported earnings per share of -11 cents and revenue of $1.02 million. Biomerica is a company that has been in business since the 1970s. The stock was down 2% after the report was released.
Investorplace · 04/13 02:52
Financial Report: Q3 2022 - Q3 2023
Press release · 04/13 00:21
BIOMERICA Q3 REVENUE USD 1 MILLION
Reuters · 04/12 23:23
BIOMERICA REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS
Reuters · 04/12 23:23
Press Release: Biomerica Reports Third Quarter 2024 Financial Results
Biomerica Reports Third Quarter 2024 Financial Results. Fiscal Discipline Leads to Improvement as Loss per Share Narrows to $0.27. InFoods IBS Positive Clinical Data to be Presented at the 2024 Digestive Disease Week (DDW) Conference in Washington DC. Company in discussions with labs for use of its recently FDA 510(k) cleared HP Detect test.
Dow Jones · 04/12 23:23
Biomerica Received Decision Grant European Patent Number EP3497447 Titled "COMPOSITIONS, DEVICES, AND METHODS OF DEPRESSION SENSITIVITY TESTING"
Benzinga · 04/11 18:05
Weekly Report: what happened at BMRA last week (0401-0405)?
Weekly Report · 04/08 12:07
More
Webull provides a variety of real-time BMRA stock news. You can receive the latest news about Biomerica Inc through multiple platforms. This information may help you make smarter investment decisions.
About BMRA
Biomerica, Inc. is a biomedical technology company. The Company develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians’ offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. It is also engaged in the research, development, commercialization and in certain cases regulatory approval, of patented, diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases. The Company's InFoods IBS product uses a simple blood sample and is designed to identify patient-specific foods that, when removed from the diet, may alleviate IBS symptoms such as pain, bloating, diarrhea and constipation. The Company’s two subsidiaries, Biomerica de Mexico, which is used for assembly/manufacturing and BioEurope GmbH, which acts as a distributor of Biomerica products in certain markets.